Response to: Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure.

Autor: Buti M; Liver Unit, Hospital Vall d'Hebrón, Barcelona and CIBER-EHD del Instituto Carlos III, Barcelona, Spain. Electronic address: mariabutiferret@gmail.com., Heo J; Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea. Electronic address: jheo@pusan.ac.kr., Lee M; GSK, Clinical Research - Hepatology, Seattle, WA, USA.
Jazyk: angličtina
Zdroj: Journal of hepatology [J Hepatol] 2024 Dec 10. Date of Electronic Publication: 2024 Dec 10.
DOI: 10.1016/j.jhep.2024.12.012
Abstrakt: Competing Interests: Declaration of Competing Interest MB has received grant support from Gilead and AbbVie, consultant fees from Gilead, AbbVie, Roche, Altimmune, and GSK, and lecture fees from Altimmune. JH has received grant support from Gilead and Roche, has received consultant fees from Roche, and lecture fees from AbbVie Korea, Roche, Yuhan Korea, Oncolys and Gilead, and is a member of an AstraZeneca steering committee. ML is an employee of and holds financial equities in GSK.
Databáze: MEDLINE